基本信息

 侯鹏,男,1974年10月,第一附属医院内分泌科副主任,博士生导师,西安交通大学第九批“腾飞”特聘教授及第一批“青年拔尖人才”,陕西省中青年科技创新领军人才,陕西省肿瘤精准医学重点实验室副主任。分别于1998、2001、2004年在兰州大学及东南大学获得学士、硕士和博士学位。2005年至2009年在美国约翰·霍普金斯大学医学院从事博士后研究,主要从事肿瘤遗传与表观遗传学的相关工作。20099月受聘西安交通大学第一附属医院,并获得光华基金资助(光华特聘教授),次年入选教育部新世纪优秀人才支持计划。近年来,课题组共获得国家自然科学基金14项、973子课题1项及其它省部级项目多项;共发表SCI论文100篇,被引用2220(数据来自Web of Science),H-index为26其中以第一及通讯作者发表SCI论文66,IF>10的论文 3篇,IF >5的论文27篇,影响因子总计超过2901篇论文入选ESI高被引论文,归入其学术领域中最优秀的 1% 之列)。此外,申请及合作申请专利3项。

 

 
代表论文(*通讯作者)
  1.  Hou P, Liu D, Xing M*. The T1790A BRAF mutation (L597Q) in childhood acute lymphoblastic leukemia is a functional oncogene. Leukemia. 2007; 21(10):2216-8. (IF: 11.702)
  2. Yang Q and Hou P*. Targeting PFKFB3 in the Endothelium for Cancer Therapy. Trends in Molecular Medicine. 2017;23(3):197-200. (IF: 10.732)
  3. Hou P, Ji M, Ge C, Shen J, Li S, He N, Lu Z*. Detection of methylation of human p16(Ink4a) gene 5-CpG islands by electrochemical method coupled with linker-PCR. Nucleic Acids Res. 2003; 31(16):e92. (IF: 10.162)
  4. Hou P, Liu D, Shan Y, Hu S, Studeman K, Condouris S, Wang Y, Trink A, El-Naggar AK, Tallini G, Vasko V, Xing M*. Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clin Cancer Res. 2007; 13(4):1161-70. (IF: 9.619; 被引频次: 234)
  5. Qu Y, Yang Q, Liu J, Shi B, Ji M, Li G, Hou P*. c-Myc is required for BRAFV600E-induced epigenetic silencing by H3K27me3 in tumorigenesis. Theranostics. 2017; 7(8):2092-2107. (IF: 8.712)
  6. Hou P*, Chen Z, Ji M, He N, Lu Z*. Real-time PCR assay for ultrasensitive quantification of DNA-binding proteins. Clin Chem. 2007; 53(4):581-6. (IF: 8.01)
  7. Hou P, Ji M, Li S, Lu Z*. Microarray-based approach for high-throughput genotyping of single-nucleotide polymorphisms with layer-by-layer dual-color fluorescence hybridization. Clin Chem. 2004; 50(10):1955-7. (IF: 8.01)
  8. Qu Y, Dang S, Wu K, Shao Y, Yang Q, Ji M, Shi B, Hou P*. TERT promoter mutations predict worse survival in laryngeal cancer patients. Int J Cancer. 2014;135(4):1008-10. (IF: 6.51)
  9. Qu Y, Shi L, Wang D, Zhang B, Yang Q, Ji M, Shi B, Hou P*. Low frequency of TERT promoter mutations in a large cohort of gallbladder and gastric cancers. Int J Cancer. 2014;134(12):2993-4. (IF: 6.51)
  10. Hou P, Ji M, Xing M*. Association of PTEN gene methylation with genetic alterations in the phosphatidylinositol 3-kinase/AKT signaling pathway in thyroid tumors. Cancer. 2008;113(9):2440-7. (IF: 5.997; 被引频次: 89)
  11. Hou P, Ji M, Yang B, Chen Z, Qiu J, Shi X, Lu Z*. Quantitative analysis of promoter hypermethylation in multiple genes in osteosarcoma. Cancer. 2006;106(7):1602-9. (IF: 5.997)
  12. Shi J, Qu Y, Li X, Sui F, Yao D, Yang Q, Shi B, Ji M, Hou P*. Increased expression of EHF via gene amplification contributes to the activation of HER family signaling and associates with poor survival in gastric cancer. Cell Death Dis. 2016;7(10):e2442. (IF: 5.965)
  13. Zhang Y, Sui F, Ma J, Ren X, Guan H, Yang Q, Shi J, Ji M, Shi B, Sun Y, Hou P*. Positive Feedback Loops between NrCAM and Major Signaling Pathways Contribute to Thyroid Tumorigenesis. J Clin Endocrinol Metab. 2017;102(2):613-24. (IF: 5.46)
  14. Qiang W, Zhao Y, Yang Q, Liu W, Guan H, Lv S, Ji M, Shi B, Hou P*. ZIC1 Is Putative Tumor Suppressor in Thyroid Cancer by Modulating Major Signaling Pathways and Transcription Factor FOXO3a. J Clin Endocrinol Metab. 2014; 99(7):E1163-72.(IF: 5.46)
  15. Cui B, Yang Q, Guan H, Shi B, Hou P*, Ji M*. PRIMA-1, a Mutant p53 Reactivator, Restores the Sensitivity of TP53 Mutant-type Thyroid Cancer Cells to the Histone Methylation Inhibitor 3-Deazaneplanocin A (DZNep). J Clin Endocrinol Metab. 2014; 99(6):E962-70. (IF: 5.46)
  16. Yang Q, Ji M, Guan H, Shi B, Hou P*. Shikonin Inhibits Thyroid Cancer Cell Growth and Invasiveness through Targeting Major Signaling Pathways.J Clin Endocrinol Metab. 2013; 98(12):E1909-17. (IF: 5.46)
  17. Hou P, Bojdani E, Xing M*. Induction of Thyroid Gene Expression and Radioiodine Uptake in Thyroid Cancer Cells by Targeting Major Signaling Pathways. J Clin Endocrinol Metab. 2010; 95(2):820-8. (IF: 5.46; 被引频次: 56)
  18. Wang Y#, Hou P#, Yu H, Wang W, Ji M, Zhao S, Yan S, Sun X, Liu D, Shi B, Zhu G, Condouris S, Xing M*. High prevalence and mutual exclusivity of genetic alterations in the phosphatidylinositol-3-kinase/akt pathway in thyroid tumors. J Clin Endocrinol Metab. 2007; 92(6):2387-90. (IF: 5.46; 被引频次: 102) #并列第一作者
  19. Hou P, Liu D, Xing M*. Genome-wide alterations in gene methylation by the BRAF V600E mutation in papillary thyroid cancer cells. Endocr Relat Cancer. 2011;18(6):687-97. (IF: 5.267)
  20. Qu Y, Dang S, Hou P*. Gene methylation in gastric cancer. Clin Chim Acta. 2013;424:53-65. (ESI高被引论文,被引频次:130)
 
 
主要学术任职
  1. Am J Cancer Res. (IF: 3.264)、World J Gastroenterol. (IF: 3.365)、American Journal of Biomedical Sciences和临床医学研究与实践杂志编委;西安交通大学学报(医学版)责任编委
  2. 陕西省肿瘤联盟甲状腺癌专业委员会 副主任委员
  3. 陕西省国际医学促进会内分泌/遗传/代谢专业委员会 副主任委员
  4. 中华医学会内分泌分会 青年委员
  5. 中华医学会陕西省内分泌分会 委员
  6. 中华医学会内分泌分会“转化医学学组”成员
  7. 中国细胞生物学会青年委员会 委员
  8. 陕西省抗癌协会生物样本库专业委员会 常务委员
  9. 陕西省抗癌协会肿瘤标志物专业委员会 常务委员
  10. 国家自然科学基金重点项目和面上项目一审专家
 
研究方向
1)肿瘤遗传与表观遗传学;2)肿瘤早期诊断与个体化治疗;2)肿瘤分子靶向治疗
 
联系方式
电话:029-85324749 (O)
 

欢迎报考!